CCND1 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment of chronic myelogenous leukemia (CML) cells K562 cells and imatinib-resistant K562R cells with CTD induces mitotic arrest, mediated by activation of the cyclin B1/Cdc2 complex and downregulation of cyclin D1.